Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gadolinium
Drug ID BADD_D00989
Description Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
Indications and Usage Not Available
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB12091
KEGG ID Not Available
MeSH ID D005682
PubChem ID 23982
TTD Drug ID Not Available
NDC Product Code Not Available
UNII AU0V1LM3JT
Synonyms Gadolinium
Chemical Information
Molecular Formula Gd
CAS Registry Number 7440-54-2
SMILES [Gd]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glioma17.20.01.004; 16.30.01.004--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.042--Not Available
Injection site haemorrhage12.07.03.005; 08.02.03.005; 24.07.01.010--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Lacrimation increased06.08.02.004--
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages